Rhythm Pharmaceuticals (RYTM) Earnings Analysis
Rhythm Pharmaceuticals (RYTM) has no confirmed upcoming earnings date. Last quarter (2026-02-26) it beat with EPS -0.73 USD vs -0.79 USD est (+7.6%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -33.22.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RYTM next report earnings?
No confirmed upcoming earnings date is currently scheduled for RYTM. This page updates as the calendar is published.
RYTM earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | -0.73 USD | -0.79 USD | +7.6% | Beat |
| 2025-02-26 | -0.72 USD | -0.69 USD | -4.3% | Miss |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
RYTM valuation and analyst view
| Trailing P/E | -33.22 |
|---|---|
| Trailing EPS | -2.98172 USD |
| Price / book | 57.50 |
| Dividend yield | 0.00% |
| Market cap | 7.08B |
| Analyst consensus | Buy (21 buy / 0 hold / 0 sell) |
| Avg price target | 144.6 USD |
Related research pages
Frequently asked questions
When is Rhythm Pharmaceuticals (RYTM)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RYTM. This page updates as the calendar is published.
Did RYTM beat earnings last quarter?
In its 2026-02-26 report, RYTM posted EPS of -0.73 USD versus a -0.79 USD estimate — a beat of 7.6%.
What is RYTM's earnings track record?
Over the last 2 reported quarters with consensus data, RYTM beat estimates 1 times (50%).
What is RYTM's current P/E ratio and EPS?
RYTM trades at a trailing P/E of -33.22 on trailing EPS of -2.9817198418229105 USD.
What do analysts rate RYTM?
Analyst consensus is "Buy" across 21 ratings (0 strong buy, 21 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 144.6 USD.